ArticleEuropean journal of obstetrics & gynecology and reproductive biology: X2026
Visceral adiposity and insulin resistance in polycystic ovarian syndrome - A cross-sectional, observational study.
Article in European journal of obstetrics & gynecology and reproductive biology: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insulin resistance (IR) is the pathogenic mechanism responsible for polycystic ovarian syndrome (PCOS) and excess of visceral adipose tissue (VAT). Objectives: We examined VAT and IR using the homeostasis model assessment (HOMA) in patients with PCOS and controls. Study design: In this cross-sectional, observational study, we included 74 patients newly diagnosed with PCOS and a similar number of age- and weight-matched healthy women as controls. Haematological, biochemical, and hormonal parameters were estimated from a fasting blood sample taken during the follicular phase, and VAT was assessed using dual-energy X-ray absorptiometry (DEXA). The results were analyzed using relevant statistical methods, and a p-value of less than 0.05 was considered significant. Results: The study participants (n = 148) had a mean age of 23.6 ± 3.7 years, body weight of 59.9 ± 11.6 kg, and a body mass index (BMI) of 25.2 ± 3.2 kg/m². Among the PCOS patients, 25 had a normal BMI and 49 were obese. The VAT (grams) was comparable between patients (484.3 ± 218.2) and controls (439.9 ± 212.8) (p = 0.1591). The percentage of fat in the trunk/legs was higher in PCOS patients (0.9 ± 0.1) than controls (0.87 ± 0.08) (p = 0.0329). Correlation analysis revealed a positive correlation of 17-hydroxy progesterone (17OHP) with many adiposity parameters in both groups (p < 0.001). Conclusion: The VAT was similar in PCOS and controls, and HOMA showed significant correlation with VAT. 17 OHP correlated with many metabolic and hormonal parameters in both groups. Further studies with larger sample sizes are needed to confirm our findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.